# Inder S. Anand

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/inder-s-anand/

## Facts

| Field | Value |
| --- | --- |
| Citations | 56,561 |
| Field | Heart Failure Treatment and Management |
| h-index | 113 |
| i10-index | 377 |
| Last Known Institution | University of Minnesota |
| OpenAlex ID | https://openalex.org/A5007353842 |
| ORCID iD | 0000-0003-1308-4963 |
| Works | 681 |

## Researcher papers

Showing 12 of 29.

- [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/)
- [Spironolactone for Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/spironolactone-for-heart-failure-with-preserved-ejection-fraction/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [The Seattle Heart Failure Model](https://scholariq.org/papers/the-seattle-heart-failure-model/)
- [Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative](https://scholariq.org/papers/cardio-renal-syndromes-report-from-the-consensus-conference-of-the-acute/)
- [Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial](https://scholariq.org/papers/regional-variation-in-patients-and-outcomes-in-the-treatment-of-preserved/)
- [Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)](https://scholariq.org/papers/changes-in-brain-natriuretic-peptide-and-norepinephrine-over-time-and-mortality/)
- [Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure](https://scholariq.org/papers/prognostic-value-of-very-low-plasma-concentrations-of-troponin-t-in-patients/)
- [Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure](https://scholariq.org/papers/cardiac-myosin-activation-with-omecamtiv-mecarbil-in-systolic-heart-failure/)
- [Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure](https://scholariq.org/papers/treatment-of-anemia-with-darbepoetin-alfa-in-systolic-heart-failure/)
- [Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure](https://scholariq.org/papers/sacubitril-valsartan-across-the-spectrum-of-ejection-fraction-in-heart-failure/)
- [Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes](https://scholariq.org/papers/effect-of-dapagliflozin-on-worsening-heart-failure-and-cardiovascular-death-in/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Cardiac pacing and defibrillation studies](https://scholariq.org/topics/cardiac-pacing-and-defibrillation-studies/)
- [Cardiac Fibrosis and Remodeling](https://scholariq.org/topics/cardiac-fibrosis-and-remodeling/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Researcher university

- [University of Minnesota](https://scholariq.org/institutions/university-of-minnesota/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.